ArticleRespirology case reports2026
Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon-Like Peptide 1 Agonist: A Case Report.
Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- EASE-CF: dietitian-led weight-loss intervention for adults with cystic fibrosis and excess weight: protocol for a feasibility randomised controlled trial.BMJ open respiratory research · 2026Article
- Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon-Like Peptide 1 Agonist: A Case Report.Respirology case reports · 2026Article
- Sodium Glucose-Like Co-Transporter 2 Inhibitor (SGLT2i) Use in Adults With Cystic Fibrosis.Respirology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) modulator therapies can lead to rapid and excessive weight gain. Obesity in CF can lead to undesirable metabolic complications including type 2 diabetes. Therefore, glucagon-like peptide 1 (GLP-1) agonists which can facilitate weight loss and improve metabolic profiles are increasingly prescribed to people with CF. We present the first case report documenting serial changes in body composition and bone mineral density over a 3-year period in an adult with CF, obesity and diabetes treated with Semaglutide and Elexacaftor/Tezacaftor/Ivacaftor (ETI). Our case experienced substantial weight gain following ETI initiation which exacerbated hyperglycaemia. This prompted initiation of Semaglutide, which over 12 months led to 14.8% total body weight loss and significant glycaemic improvement. However, serial assessments revealed declines in absolute muscle mass, muscle strength and bone mineral density despite prescription of tailored exercise and nutritional interventions. Our findings highlight the need for cautious use of GLP-1 in people with CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.